VIR Q1 2025 Earnings — Vir Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

VIRVir Biotechnology, Inc.

$1B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-94.6% YoY

Gross Profit

-$115M-3779.1% margin

Operating Income

-$140M-4602.5% margin

Net Income

-$121M-3989.6% margin

EPS (Diluted)

$-0.88

QoQ Revenue Growth

-75.5%

Cash Flow

Operating Cash Flow

-$78M

Free Cash Flow

-$80M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$264M

Stockholders' Equity

$1.0B

Cash & Equivalents

$274M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$56M	-94.6%
Gross Profit	-$115M	-$42M	-171.8%
Operating Income	-$140M	-$80M	-74.3%
Net Income	-$121M	-$65M	-85.3%

Revenue Segments

Contract Revenue

$2M60%

Grant

$1M40%

Geographic Segments

Non-US

$2M60%

UNITED STATES

$1M40%